Colivelin Peptide: ADNF-Humanin Hybrid Neuroprotection Explained

Colivelin is a designed laboratory peptide, not a clinic-ready drug. It was engineered to combine two separate neuroprotective molecules into a single chimeric chain: a fragment of activity-dependent neurotrophic factor (ADNF) attached to the front of a strengthened version of Humanin, a small mitochondria-derived peptide. The goal was to capture the protective signaling of both parents in one molecule, and in cell culture the result was strikingly potent.

That potency is exactly why Colivelin deserves a careful, honest write-up. Femtomolar activity in a dish reads like a headline, but it is not the same as a proven, dosable human therapy. Colivelin has spent its entire documented life in laboratories. It is an experimental research compound with no approval, no registered clinical trial, and no established human dose.

This guide is educational and not medical advice. Colivelin is not an approved medicine and is not a supplement. Nothing here should be read as a protocol, a recommendation, or a suggestion that it is safe or appropriate for human use.

Colivelin At A Glance

How A Hybrid Peptide Was Built

To understand Colivelin, it helps to meet its two parents.

Humanin is a short peptide encoded within mitochondrial DNA that was originally identified in tissue from an Alzheimer's disease brain that had been relatively spared from degeneration. It suppresses neuronal death linked to amyloid-beta and to familial Alzheimer's mutations. A single amino-acid swap, replacing serine 14 with glycine, produces a much more potent analog known as S14G-Humanin or HNG. Colivelin uses an even more refined Humanin derivative, AGA-(C8R)HNG17.

ADNF, activity-dependent neurotrophic factor, is a protein released by glia that protects neurons through a short active core peptide. ADNF and the related ADNP sequences signal through a separate calcium-dependent route.

The Keio University team reasoned that linking these two molecules might let each contribute its own protective signal. They fused the ADNF active fragment to the N-terminus of AGA-(C8R)HNG17 and named the product Colivelin. In their 2005 Journal of Neuroscience report, the hybrid suppressed neuronal death at roughly 100 femtomolar, about 100-fold lower than the Humanin derivative alone and orders of magnitude below native Humanin. That is the source of the "femtomolar-acting" description that follows Colivelin around.

Proposed Mechanism

The central claim about Colivelin is that it does two things at once.

The Humanin portion is reported to bind a cell-surface receptor complex and trigger a JAK2/STAT3 pro-survival cascade. STAT3 is a transcription factor that, when activated, can shift a stressed neuron away from programmed cell death.

The ADNF portion is reported to engage a separate pathway that runs through Ca2+/calmodulin-dependent protein kinase IV, or CaMKIV. Activating two independent survival routes simultaneously is the proposed reason the hybrid is more potent than either parent peptide given alone.

This dual-pathway, mitochondria-linked framing is why Colivelin is often grouped with other mitochondrial and longevity-adjacent peptides such as MOTS-c and SS-31 (elamipretide). The important difference is that those comparators have at least reached human testing, whereas Colivelin has not. If the underlying signaling vocabulary is new to you, the primer on what peptides are is a useful starting point.

Preclinical Evidence, And Its Limits

Colivelin's research record is genuinely interesting, and it is also entirely preclinical. Keeping both of those facts in view is the whole point.

The Alzheimer's work appeared in the Journal of Neuroscience (Chiba et al., 2005) and was followed by a nasal-delivery study in Neuropsychopharmacology and review coverage in Molecular Neurobiology and CNS Drug Reviews. The ALS survival study (Chiba et al., 2006) reported that intracerebroventricular Colivelin, dosed in picomole-to-nanomole quantities, prolonged survival of G93A-SOD1 transgenic mice.

Here is the honest summary. The signal across these studies is consistent and the potency is unusual. But every result lives in cells or rodents, many of the most convincing experiments delivered the peptide directly into the brain, and the field of neurodegeneration is littered with compounds that rescued mice and then failed in people. After roughly two decades, Colivelin has not advanced to registered human clinical trials. That absence is itself a key data point.

Safety: What Is And Is Not Known

There is no human safety database for Colivelin. The table below frames what the gap actually means rather than implying a known safety profile.

The practical reading is straightforward. Absence of reported harm is not the same as evidence of safety. A molecule that powerfully drives pro-survival and proliferative signaling needs careful long-term toxicology before anyone can make a safety claim, and that work has not been published. For general context on why peptide duration matters, see the peptide half-life explainer.

How To Evaluate A Colivelin Claim

Because Colivelin sits in the gap between impressive science and aggressive marketing, a short checklist helps.

First, check the source. Real Colivelin data comes from PubMed-indexed journals and the Keio University group, not from vendor product pages.

Second, watch for the femtomolar headline. Extreme in-vitro potency is true, but it describes a dish, not a person, and it is routinely used to oversell.

Third, ask about route. The most convincing rodent results used intracerebroventricular injection straight into the brain. Peripheral and nasal routes were explored, but none establish a human dosing path.

Fourth, ask for human trials. There are none registered. Any claim of human benefit is unsupported.

Fifth, compare honestly. Even better-studied mitochondrial peptides like MOTS-c and SS-31, and brain-targeted mixtures like cerebrolysin, remain investigational. Colivelin is earlier-stage than all of them.

Bottom Line

Colivelin is a clever piece of peptide engineering. By fusing an ADNF fragment to a potent Humanin derivative, its designers created a molecule that protects cultured neurons at femtomolar concentrations and that extended survival in Alzheimer's and ALS mouse models through a proposed dual CaMKIV-plus-STAT3 mechanism.

That is also where the story stops. Colivelin is research-only. It has no approval, no registered human trial, no established human dose, and no human safety data. The most persuasive animal experiments delivered it directly into the brain, and a long history of neurodegeneration drugs warns against reading mouse survival as human promise. Colivelin is best understood as an interesting neuroscience tool and an unproven hypothesis, not as a therapy.

References

1. Chiba T, et al. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus. Journal of Neuroscience, 2005.

2. Chiba T, Nishimoto I, Aiso S, Matsuoka M. Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide Colivelin. Molecular Neurobiology, 2007.

3. Chiba T, et al. Colivelin prolongs survival of an ALS model mouse. Biochemical and Biophysical Research Communications, 2006.

4. Yamada M, et al. Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease. Neuropsychopharmacology, 2008.

5. Matsuoka M, Hashimoto Y, Aiso S, Nishimoto I. Humanin and colivelin: neuronal-death-suppressing peptides for Alzheimer's disease and amyotrophic lateral sclerosis. CNS Drug Reviews, 2006.

6. Arakawa T, et al. Activity-dependent neurotrophic factor, ADNF, determines the structure characteristics of Colivelin, a fusion protein of ADNF9 and Humanin analog. Journal of Peptide Science, 2008.

7. Hashimoto Y, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta (Humanin). PNAS, 2001.

8. Hashimoto Y, et al. Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer's disease-relevant insults. Journal of Neuroscience, 2001.